Taiho Oncology Patient Support Services

Featured Spotlight

Support Services Directory

Recent advancements in cancer treatments have revolutionized cancer care. The use of genetic mutations to guide therapy, and continued innovations in immunotherapies, targeted drugs, radiation, and chemotherapy have improved patients’ health outcomes and quality of life.1

The 5-year relative survival rate for all cancers diagnosed between 2005 and 2011 increased to 69%, a significant increase from the 49% rate for cancer diagnosed between 1975 and 1977.2 The improvement in survival rates can be attributed to the current trends of earlier diagnosis and continuing innovations in cancer therapies.2

Nevertheless, cancer remains a leading cause of death in the United States.1 According to the American Cancer Society, more than 15 million patients with cancer were living in the United States in 2016, and that number is expected to exceed 20 million in 2026.3

The United States’ commitment to accelerating cancer research was highlighted in 2016, with Vice President Joe Biden’s launch of the Cancer Moonshot initiative, which aims to make more therapies available to more patients, while improving cancer prevention and early diagnosis, with the ultimate goal of curing cancer. Indeed, the oncology drug pipeline continues to have a large share of the drug pipeline, as evident by its 63% increase in the past 10 years,4 a trend that is bound to accelerate with the Cancer Moonshot initiative in the future.

Yet this innovation comes with a cost, and much of the cost burden today has been shifted to patients, making affordability and access key concerns for patients with cancer. The global cost of cancer therapies and supportive care drugs reached $107 billion in 2015, which is projected to exceed $150 billion by 2020.4

Increasing costs have prompted insurance companies to shift a larger portion of care to patients in the form of high premiums, deductibles, and copayments, resulting in significantly high out-of-pocket expenses for patients. This financial toxicity is leading to lack of adherence, which has been shown to worsen survival outcomes.5 Young adults, minorities, and lower-income Americans are especially vulnerable to the harmful effects of financial toxicity.5,6

Cost discussions between patients and physicians are becoming an important part of informed decision-making when selecting cancer treatments, and the National Comprehensive Cancer Network encourages these discussions.7

Many support programs are available today for patients with cancer who are in need of financial assistance. The following directory provides an overview of the many patient support services provided by pharmaceutical companies, nonprofit organizations and foundations, and federal programs.


  1. Dizon DS, Krilov L, Cohen E, et al. Clinical cancer advances 2016: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2016;34:987-1011.
  2. American Cancer Society. Cancer facts and figures 2016. 2016. www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf. Accessed December 12, 2016.
  3. American Cancer Society. Cancer treatment and survivorship facts and figures 2016-2017. 2016. www.cancer.org/acs/groups/content/@research/documents/document/acspc-048074.pdf. Accessed December 12, 2016.
  4. IMS Health. Global oncology trend report: a review of 2015 and outlook to 2020. 2015. www.imshealth.com/en/thought-leadership/quintiles-ims-institute/reports/global-oncology-trend-report-a-review-of-2015-and-outlook-to-2020#download-exhibits. Accessed December 13, 2016.
  5. Zafar SY, Abernethy AP. Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park). 2013;27:80-149.
  6. Landwehr MS, Watson SE, Macpherson CF, et al. The cost of cancer: a retrospective analysis of the financial impact of cancer on young adults. Cancer Med. 2016;5:863-870.
  7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks. www.nccn.org/evidenceblocks/. Accessed December 13, 2016.